Bridges N A, Cooke A, Healy M J, Hindmarsh P C, Brook C G
London Centre for Paediatric Endocrinology and Metabolism, Middlesex Hospital, UK.
Clin Endocrinol (Oxf). 1995 Feb;42(2):135-40. doi: 10.1111/j.1365-2265.1995.tb01853.x.
Ovarian ultrasonography may be helpful in distinguishing the various types of precocious puberty, and the ovarian appearances increasingly influence choice of therapy in these girls. We examined retrospectively the ovarian volume and prevalence of polycystic ovarian appearance at ultrasound in girls with sexual precocity.
Ultrasound examinations were obtained from girls who presented with sexual precocity. If there were several scans from the same individual, the latest was analysed.
The girls were divided into groups: untreated central precocious puberty (n = 25), central precocious puberty treated with GnRH analogue (n = 18) or with GnRH analogue and recombinant human GH (n = 11), girls who had stopped treatment with GnRH analogue and GH (n = 12), premature thelarche and thelarche variant (n = 15) and premature adrenarche (n = 14).
Ovarian volume was calculated and the ovaries were assessed for polycystic appearance using standard criteria. Ovarian volume standard deviation (SD) scores were calculated using means and standard deviations derived from a control population and compared using analysis of variance. Differences from control data were assessed using Student's t-test.
Ovarian volume SD scores for all the groups studied were greater than those for control subjects. Girls who had stopped treatment with GnRH analogue and GH had mean ovarian volume of 6.98 ml and ovarian volume SD score (+1.72) greater than that of girls having treatment with GnRH analogue alone (+1.24). Polycystic appearance ovaries were found in 83% of scans in girls who had stopped treatment with GnRH analogue and GH. The ovarian volume SD score of girls with premature adrenarche was less than that of girls with untreated central precocious puberty.
Girls with central precocious puberty had large ovaries which did not return to a volume appropriate for age. Girls treated with GnRH analogue and GH developed very large ovaries when they stopped treatment, and had an increased prevalence of ovaries with a polycystic appearance. Central precocious puberty, or some aspect of its treatment, results in an increased prevalence of polycystic ovarian appearance.
卵巢超声检查可能有助于区分不同类型的性早熟,而且卵巢表现对这些女孩治疗方案的选择影响越来越大。我们回顾性研究了性早熟女孩的卵巢体积以及超声检查时多囊卵巢表现的发生率。
对出现性早熟的女孩进行超声检查。如果同一个体有多次扫描,分析最新的一次。
女孩被分为以下几组:未经治疗的中枢性性早熟(n = 25)、用促性腺激素释放激素(GnRH)类似物治疗的中枢性性早熟(n = 18)或用GnRH类似物和重组人生长激素(GH)治疗的中枢性性早熟(n = 11)、已停止GnRH类似物和GH治疗的女孩(n = 12)、单纯乳房早发育和变异型乳房早发育(n = 15)以及肾上腺功能初现提前(n = 14)。
计算卵巢体积,并根据标准标准评估卵巢是否有多囊表现。卵巢体积标准差(SD)分数通过对照人群的均值和标准差计算得出,并采用方差分析进行比较。与对照数据的差异采用Student t检验进行评估。
所有研究组的卵巢体积SD分数均高于对照组。已停止GnRH类似物和GH治疗的女孩平均卵巢体积为6.98 ml,卵巢体积SD分数(+1.72)高于仅用GnRH类似物治疗的女孩(+1.24)。在已停止GnRH类似物和GH治疗的女孩中,83%的扫描发现有多囊表现的卵巢。肾上腺功能初现提前女孩的卵巢体积SD分数低于未经治疗的中枢性性早熟女孩。
中枢性性早熟女孩的卵巢较大,且不会恢复到适合年龄的体积。用GnRH类似物和GH治疗的女孩在停止治疗时卵巢会变得非常大,且多囊表现卵巢的发生率增加。中枢性性早熟或其治疗的某些方面会导致多囊卵巢表现的发生率增加。